GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer
GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer
复制标题
GDF15 预测一线化疗期间的铂类反应，并且可以作为上皮性卵巢癌中 CA125 的补充诊断血清生物标志物
DOI：
10.1186/s12885-018-4246-4
复制
发表时间：
2018-03-27
期刊：
影响因子：
3.8
通讯作者：
Zhang, Wei
中科院分区：
文献类型：
--
作者：
Zhao, Dan;Wang, Xiaobing;Zhang, Wei
背景生长分化因子 15 (GDF15) 作为上皮性卵巢癌 (EOC) 的新型生物标志物引起了广泛关注。研究重点是 GDF15 作为诊断检测，而 GDF15 在 EOC 患者中的预后判断仍有待明确阐明。本研究旨在探讨GDF15水平与EOC患者的临床病理特征、化疗反应和临床结果的关系。方法对122例原发性EOC患者的血清进行GDF15和血清癌抗原125（CA125）分析。所有病例均接受减瘤手术和一线化疗，样本均在减瘤手术和一线化疗前采集。随后记录临床特征、化疗反应和无进展生存期(PFS)。结果血清GDF15水平升高与FIGO分期和淋巴结转移显着相关。 GDF15 和 CA125 检测在 EOC 的诊断中是互补的，并且可以同时进行分析。化疗耐药的 EOC 患者（中位数为 1225.0 pg/mL）的 GDF15 显着高于化疗敏感患者（中位数为 824.2 pg/mL；P= 0.013）。多变量分析显示，高表达的GDF15是122例EOC病例PFS（P= 0.026）的独立负面预后指标。此外，血清CA125水平高的患者与减瘤手术次优（P= 0.043）显着相关。结论我们的结果提供了有价值的证据，表明GDF15与一线化疗耐药相关，高表达的GDF15是EOC患者较短PFS的有力且独立的指标。
BackgroundGrowth differentiation factor 15 (GDF15) has attracted much interest as a novel biomarker for epithelial ovarian carcinoma (EOC). Research focus has been directed at GDF15 as a diagnostic detection, while the prognostic determination of GDF15 in EOC patients remains to be clearly elucidated. The present study aimed to investigate GDF15 level relative to clinicopathological characters, chemoresponse, and clinical outcome of EOC patients.MethodsSerum from 122 patients with primary diagnosed EOC were analyzed for GDF15 and serum cancer antigen 125 (CA125). All cases were treated with debulking surgery and first-line chemotherapy, and samples were obtained just before debulking surgical treatment and first-line chemotherapy. Subsequently, clinical characteristics, responses to chemotherapy and progression-free survival (PFS) were recorded.ResultsIncreasing levels of serum GDF15 was significantly associated with FIGO stage and lymphonodus metastasis. GDF15 and CA125 detection are complementary in the diagnosis of EOC and can be simultaneously profiled. The chemo-resistant EOC patients (median, 1225.0 pg/mL) showed significantly higher GDF15 than chemo-sensitive patients (median, 824.2 pg/mL;P= 0.013). Highly expressed GDF15 was an independent negative prognostic indicator in the PFS (P= 0.026) of the 122 EOC cases in the multivariate analysis. Additionally, patients with high level of serum CA125 significantly associated with suboptimal (P= 0.043) debulking surgery.ConclusionsOur results provide valuable evidence that GDF15 is related with first-line chemo-resistance, with highly expressed GDF15 being a strong and an independent indicator of shorter PFS in EOC patients.